Back to top
more

GSK PLC Sponsored ADR (GSK)

(Delayed Data from NYSE)

$38.55 USD

38.55
3,728,100

-0.41 (-1.05%)

Updated Oct 18, 2024 04:00 PM ET

After-Market: $38.66 +0.11 (0.29%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (87 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Glaxo (GSK) Beats Q2 Earnings, Misses Sales

Glaxo's (GSK) Q2 earnings beat estimate, with revenue missing the same. Glaxo lowered its core 2017 earnings growth in the quarter, with no Advair generics are launched this year.

    The Zacks Analyst Blog Highlights: Alphabet, GlaxoSmithKline, T-Mobile, Northrop Grumman and CSX

    The Zacks Analyst Blog Highlights: Alphabet, GlaxoSmithKline, T-Mobile, Northrop Grumman and CSX

      Mark Vickery headshot

      Top Stock Reports for Alphabet, GlaxoSmithKline & T-Mobile

      Today's Research Daily features new research reports on 16 major stocks, including Alphabet (GOOGL), GlaxoSmithKline (GSK), and T-Mobile (TMUS).

        Emergent Inks Agreement to Acquire Anthrax Drug Raxibacumab

        Emergent's shares inched up post announcement of its deal inked with GlaxoSmithKline to acquire the latter's anthrax monoclonal antibody raxibacumab.

          What Lies in Store for Glaxo (GSK) this Earnings Season?

          The performance of GlaxoSmithKline plc's (GSK) new products is likely to be good. Vaccines acquired from Novartis are likely to drive revenues and ease the impact of the loss of key drug, Advair.

            Puma's (PBYI) Breast Cancer Drug Neratinib Gets FDA Approval

            Puma Biotechnology, Inc's (PBYI) lead breast cancer candidate neratinib is approved by FDA and is set to be commercially available in September under the brand name, Nerlynx.

              Gilead (GILD) Application for HIV Drug Validated in EU

              Gilead Sciences, Inc. (GILD) announced that the company's Marketing Authorization Application for once-daily single tablet for the treatment of HIV-1 infection in adults has been fully validated by the European Medicines Agency.

                Gilead (GILD) Application for HIV Drug Validated in EU

                Gilead Sciences, Inc. (GILD) announced that the company's Marketing Authorization Application for once-daily single tablet for the treatment of HIV-1 infection in adults has been fully validated by the European Medicines Agency.

                  Puma (PBYI) Ends Patient Enrollment in Phase III Cancer Trial

                  Puma Biotechnology, Inc. (PBYI) announced that it has completed enrollment of patients in a phase III study to evaluate its lead pipeline candidate PB272 in combination with Xeloda for treatment of third-line HER2-positive metastatic breast cancer.

                    Amgen's Colorectal Cancer Drug Gets FDA Nod to Expand Label

                    Amgen, Inc. (AMGN) announced that the FDA has approved a label expansion of its colorectal cancer drug, Vectibix.

                      Novartis Gets EC Nod for Lung Cancer Drug's Label Expansion

                      Novartis AG (NVS) announced that the European Commission has approved a label expansion of lung cancer drug drug Zykadia.

                        Novartis' Erelzi, Biosimilar of Enbrel Approved In Europe

                        Novartis AG (NVS) announced that the European Commission (EC) has approved Erelzi ??? the biosimilar version of Enbrel.

                          Novartis Cardiovascular Drug Positive, NSCLC Drug Approved

                          Shares of Novartis AG (NVS) were up after the company announced positive top-line results from the global phase III study, CANTOSon cardiovascular drug.

                            Glaxo's (GSK) Shingles Candidate Phase III Data Positive

                            GlaxoSmithKline plc (GSK) announced positive top-line results from a phase III revaccination study on its shingles vaccine candidate, Shingrix, in older patients.

                              Novartis Announces Positive Results for Cardiovascular Drug

                              Novartis AG (NVS) announced top-line results from the global phase III study, CANTOS on cardiovascular drug.

                                Novartis (NVS) Biosimilar of MabThera Approved in the EU

                                Novartis AG (NVS) announced that its generic arm, Sandoz, has received European Commission (EC) approval for Rixathon.

                                  GlaxoSmithKline's Benlysta Positive in Continuation Trial

                                  GlaxoSmithKline plc (GSK) announced positive results from a phase II continuation study evaluating the efficacy and safety of its marketed drug, Benlysta, in combination with standard of care for treatment systemic lupus erythematosus (SLE).

                                    Should Value Investors Pick GlaxoSmithKline (GSK) Stock Now?

                                    Let's put GlaxoSmithKline PLC (GSK) stock into this equation and find out if it is a good choice for value-oriented investors right now.

                                      Puma (PBYI) Stock Surges as Neratinib Nears FDA Approval

                                      Puma's stock has significantly outperformed the Zacks classified Medical-Biomed/Genetics industry in the year so far after an FDA advisory committee recommended approval for neratinib in May this year.

                                        Gilead (GILD) Submits NDA for HIV Combination Therapy Regimen

                                        Gilead Sciences, Inc. (GILD) announced that it has submitted a NDA to the FDA for an investigational HIV combination therapy regimen.

                                          Novartis Presents Positive Data on CAR-T Cell Therapy Drug

                                          Novartis AG (NVS) announced data from an interim analysis from a phase II study on lymphoma candidate.

                                            Inovio's HPV Immunotherapy Moves to Phase III, Stock Rises

                                            Inovio Pharmaceuticals, Inc (INO) initiated a pivotal phase III REVEAL study to evaluate the safety and efficacy of immunotherapy, VGX-3100 to treat cervical dysplasia caused by human papillomavirus.

                                              Novartis' (NVS) Tasigna Receives Label Update Nod in EU

                                              Novartis AG (NVS) announced that the EC has approved the inclusion of Treatment-free Remission (TFR) data in the oncology drug Tasigna's label.

                                                Merck's Cancer Drug Keytruda Positive in Clinical Studies

                                                Merck & Co., Inc. (MRK) announced positive data from a phase III study KEYNOTE-024, evaluating its anti-PD-1 therapy, Keytruda (pembrolizumab) for first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC).

                                                  Novartis Presents Data on Tafinlar-Mekinist Combination

                                                  Novartis AG (NVS) announced results from a phase II study, BRF113220, on the combination of Tafinlar and Mekinist at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO).